Trials / Completed
CompletedNCT01059539
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 403 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the long-term safety, tolerability, and pharmacokinetics of cariprazine in patients with bipolar I disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cariprazine | Cariprazine was supplied in capsules. |
Timeline
- Start date
- 2010-02-28
- Primary completion
- 2012-02-29
- Completion
- 2012-02-29
- First posted
- 2010-02-01
- Last updated
- 2019-06-13
- Results posted
- 2019-06-13
Locations
35 sites across 4 countries: United States, Hungary, Poland, Spain
Source: ClinicalTrials.gov record NCT01059539. Inclusion in this directory is not an endorsement.